Neuroimaging markers and disability scales in multiple sclerosis: A systematic review and meta-analysis

Multiple sclerosis (MS) is a central nervous system disorder marked by progressive neurological impairments. Magnetic resonance imaging (MRI) parameters are key paraclinical measures that play a crucial role in the diagnosis, prognosis, and monitoring of MS-related disability. This study aims to ana...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PloS one Jg. 19; H. 12; S. e0312421
Hauptverfasser: Mirmosayyeb, Omid, Yazdan Panah, Mohammad, Mokary, Yousef, Mohammadi, Mohammad, Moases Ghaffary, Elham, Shaygannejad, Vahid, Weinstock-Guttman, Bianca, Zivadinov, Robert, Jakimovski, Dejan
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States Public Library of Science 05.12.2024
Public Library of Science (PLoS)
Schlagworte:
Analysis
Biological markers
Biology and Life Sciences
Brain
Brain - diagnostic imaging
Brain - pathology
Care and treatment
Central nervous system
Confidence intervals
Correlation coefficient
Correlation coefficients
Diagnosis
Disability Evaluation
Heterogeneity
Humans
Image processing
Lesions
Magnetic resonance
Magnetic resonance imaging
Magnetic Resonance Imaging - methods
Medical imaging
Medicine and Health Sciences
Meta-analysis
Multiple sclerosis
Multiple Sclerosis - diagnostic imaging
Multiple Sclerosis - pathology
Neuroimaging
Neuroimaging - methods
Parameters
Physical Sciences
Research and Analysis Methods
Science Policy
Software
Spinal cord
Standard scores
Substantia grisea
Systematic review
United States
ISSN:1932-6203, 1932-6203
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Multiple sclerosis (MS) is a central nervous system disorder marked by progressive neurological impairments. Magnetic resonance imaging (MRI) parameters are key paraclinical measures that play a crucial role in the diagnosis, prognosis, and monitoring of MS-related disability. This study aims to analyze and summarize the existing literature on the correlation between MRI parameters and disability in people with MS (pwMS). The PubMed/MEDLINE, Embase, Scopus, and Web of Science databases were searched from inception to July 19, 2024, and a meta-analysis was carried out using R software version 4.4.0 and the random effects model used to determine the pooled correlation coefficient, with its 95% confidence interval (CI), between MRI measurements and disability scales. Among 5741 studies, 383 studies with 39707 pwMS were included. The meta-analysis demonstrated that Expanded Disability Status Scale (EDSS) had significant correlations with cervical cord volume (r = -0.51, 95% CI: -0.62 to -0.38, I2 = 0%, p-heterogeneity = 0.86, p-value<0.01), cortical lesion volume (r = 0.45, 95% CI: 0.36 to 0.53, I2 = 68%, p-heterogeneity<0.01, p-value<0.01), brain volume (r = -0.40, 95% CI: -0.47 to -0.33, I2 = 41%, p-heterogeneity = 0.05, p-value<0.05), and grey matter volume (GMV) (r = -0.36, 95% CI: -0.49 to -0.21, I2 = 0%, p-heterogeneity = 0.53, p-value<0.01), respectively. This study offers evidence suggesting that cortical lesion volume, brain volume, GMV, and MRI measurements of the spinal cord may constitute reliable indicators for assessing disability in pwMS.
Bibliographie:ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
Competing Interests: The authors declare no conflict of interest regarding the publication of this paper. Omid Mirmosayyeb, Mohammad Yazdan Panah, Yousef Mokary, Mohammad Mohammadi, Elham Moases Ghaffary, Vahid Shaygannejad and Dejan Jakimovski have nothing to disclose. Robert Zivadinov has received personal compensation from Bristol Myers Squibb, EMD Serono, Sanofi, Protembis, Janssen, 415 Capital, and Novartis for speaking and consultant fees. He received financial support for research activities from Sanofi, Novartis, Bristol Myers Squibb, Octave, Mapi Pharma, CorEvitas, Protembis and V-WAVE Medical. Bianca Weinstock-Guttman received honoraria as a speaker and/or as a consultant for Biogen Idec, Teva Pharmaceuticals, EMD Serono, Genzyme, Sanofi, Genentech, Novartis, Celgene/ BMS, Janssen and Horizon. Bianca Weinstock-Guttman received research funds from Biogen Idec, EMD Serono, Genzyme, Genentech, Sanofi, Novartis.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0312421